Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany; Berlin Institute of Health, Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin, Germany; University Hospital Montpellier, France; MACVIA-France, Montpellier, France.
Department of Clinical Immunology, Wrocław Medical University, Wrocław, Poland.
J Allergy Clin Immunol Pract. 2021 May;9(5):1805-1812. doi: 10.1016/j.jaip.2021.02.035. Epub 2021 Mar 1.
Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many international or national practice guidelines have been produced, but the evidence-based method varies and they do not usually propose care pathways. The present article considers the possible role of mobile health in AIT for allergic rhinitis/asthma. There are no currently available validated biologic biomarkers that can predict AIT success, and mobile health biomarkers have some relevance. In the current article, the following aspects will be discussed: patient stratification for AIT, symptom-medication scores for the follow-up of patients, clinical trials, as well as the approach of the European Academy of Allergy and Clinical Immunology.
变应原免疫疗法（AIT）是治疗过敏性鼻炎和/或哮喘的一种经过验证的治疗选择。已经制定了许多国际或国家实践指南，但基于证据的方法有所不同，它们通常不提出护理途径。本文考虑了移动医疗在过敏性鼻炎/哮喘的 AIT 中的可能作用。目前尚无可用的经过验证的生物生物标志物可以预测 AIT 的成功，而移动健康生物标志物具有一定的相关性。在本文中，将讨论以下方面：AIT 的患者分层、患者随访的症状-药物评分、临床试验以及欧洲过敏与临床免疫学会的方法。
